Discontinued — last reported Q4 '24
Reimbursement Of Research And Development Expenses — Revenue
Year-over-year, this metric grew by 100.0%, from -$1.50M to $0.00. Over 2 years (FY 2021 to FY 2024), Reimbursement Of Research And Development Expenses — Revenue shows a downward trend with a -100.0% CAGR.
Analysis
How to read this metric
An increase indicates higher collaborative development activity or the achievement of cost-sharing milestones, while a decrease suggests the conclusion of specific joint development projects or a shift in partnership funding structures.
Detailed definition
This metric represents revenue recognized from the reimbursement of research and development costs incurred by the compa...
Peer comparison
Comparable to 'collaboration revenue' or 'R&D cost-sharing income' reported by other biopharmaceutical companies engaged in co-development partnerships.
regn_segment_reimbursement_of_r_d_expenses_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $46.50M | $45.20M | $54.10M | $36.50M | $52.70M | $0.00 | $0.00 | $0.00 | $0.00 | -$1.50M | $0.00 | $0.00 | $0.00 | $0.00 |
| QoQ Change | — | -2.8% | +19.7% | -32.5% | +44.4% | -100.0% | — | — | — | — | +100.0% | — | — | — |
| YoY Change | — | — | — | — | +13.3% | -100.0% | -100.0% | -100.0% | — | — | — | — | — | +100.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's reimbursement of research and development expenses — revenue?
- Regeneron Pharmaceuticals (REGN) reported reimbursement of research and development expenses — revenue of $0.00 in Q4 2024.
- How has Regeneron Pharmaceuticals's reimbursement of research and development expenses — revenue changed year-over-year?
- Regeneron Pharmaceuticals's reimbursement of research and development expenses — revenue increased by 100.0% year-over-year, from -$1.50M to $0.00.
- What is the long-term trend for Regeneron Pharmaceuticals's reimbursement of research and development expenses — revenue?
- Over 2 years (2021 to 2024), Regeneron Pharmaceuticals's reimbursement of research and development expenses — revenue has grown at a -100.0% compound annual growth rate (CAGR), from $175.90M to $0.00.
- What does reimbursement of research and development expenses — revenue mean?
- Revenue earned by recovering research and development costs from external collaboration partners.